AC
AZN icon

ASB Consultores’s AstraZeneca AZN Stock Holding History

ASB Consultores’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,219
Closed -$310K – 45
2025
Q2 		$310K Buy
2,219
+329
+17% +$46.1K 0.21% 86
2025
Q1 		$278K Buy
1,890
+286
+18% +$41.4K 0.18% 85
2024
Q4 		$210K Buy
+1,604
New +$225K 0.09% 200

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ASB Consultores's AZN Position: Q3 2025 in Review

ASB Consultores sold out of AstraZeneca (AZN) in Q3 2025, closing a stake of 2,219 shares — an estimated $310K sold.

ASB Consultores first reported a position in AZN in Q4 2024 and held it in 3 quarters. The position peaked at $310K in Q2 2025. 1,287 funds tracked by Wall St. Rank hold AZN as of Q3 2025.

  • ASB Consultores reported no remaining AstraZeneca position as of Q3 2025 after selling out during the quarter.
  • ASB Consultores sold 2,219 AstraZeneca shares in Q3 2025, an estimated $310K.
  • ASB Consultores first reported a position in AstraZeneca in Q4 2024 and held it in 3 quarters.
  • ASB Consultores's AstraZeneca position peaked at $310K in Q2 2025.
  • 1,287 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2025.

Based on ASB Consultores's 13F filing for Q3 2025, filed 4 Nov 2025.